The U.S. Food and Drug Administration (FDA) has just announced a successful joint operation with the Government of India targeting counterfeit prescription drugs, counterfeit over-the-counter medications, fake medical devices, and misbranded dietary supplements containing harmful ingredients.
Today The Partnership for Safe Medicines filed comments with Health and Human Services about the dangers posed by its draft regulations for state-based Canadian drug importation programs. PSM cited historic problems with and patient harm from Canadian vendors selling counterfeit medications to U.S. patients and medical practices; showed broad opposition to the plan by Canadian stakeholders; and provides alternatives that don’t impact patient safety.
According to a report from Europol’s Intellectual Property Crime Threat Assessment 2019, “Counterfeit pharmaceuticals pose a growing threat to the EU, affecting a large number of Member States. A wide and increasingly diverse range of medicines is targeted by counterfeiters.”
The Europol ICP Threat Assessment reports that there has been an increase in seizures of counterfeit drugs used in the treatment of serious illnesses, as well as a growing number of counterfeit drug incidents affecting the legal drug supply chain.
Planet Drugs Direct, an online pharmacy based in Winnipeg, Canada, has announced a data breach. Hackers broke into their servers, exposing customers’ names, medical details, and contact and banking information. Legitscript is unequivocal in calling Planet Drugs Direct a “Rogue Internet Pharmacy,” their worst rating for online pharmacies, accusing them of violating state and federal laws.
Our infographic, “Counterfeiting by the Numbers,” highlights facts from the U.S. Department of Homeland Security’s January 2020 report, Combating Trafficking in Counterfeit and Pirated Goods, which documents the extraordinary scale of the global counterfeiting market and its effects across all economic sectors—including medicines.
The Partnership for Safe Medicines (PSM) stands with our law enforcement partners in commending the U.S. Senate and the U.S. House of Representatives for their swift passage of S.3201, which would extend the DEA’s temporary scheduling of fentanyl-related substances to be Schedule I controlled substances for an additional 15 months. Without this reauthorization, criminals could…